Search Results
Baxter Announces U.S. FDA Clearance of New Bone Graft Substitute, Actifuse Flow
Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced U.S. Food and Drug Administration (FDA) clearance of Actifuse Flow Bone Graft Substitute for use in a variety of orthopedic surgical procedures.
Baxter Unveils Olimel 7.6% High Protein Nutrition Formulation at the 2018 ESPEN Congress
Baxter International Inc.
Baxter Announces CE Mark and Regulatory Approval of New Evo IQ Infusion System for the United Kingdom, Ireland, Australia and New Zealand
Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced the CE marking of the Evo IQ Infusion System. In addition to the planned marketing of the device in the United Kingdom, Ireland and New Zealand, the Evo IQ Infusion System recently received regulatory approval by the Therapeutic Goods Administration (TGA) in Australia.
Baxter Reports Second-Quarter 2018 Results and Increases Earnings Outlook for Full-Year 2018
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the second quarter of 2018 and increased its full-year 2018 earnings guidance.
Baxter Recognized as an Inclusion and Diversity Leader
Baxter is proud to be recognized on the 2018 Diversity Best Practices (DBP) Inclusion Index of U.S.
Baxter Declares Quarterly Dividend
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.19 per share of common stock. The dividend is payable on October 1, 2018, to stockholders of record as of August 31, 2018. The indicated annual dividend rate is $0.76 per share of common stock.
Baxter to Host Second Quarter 2018 Financial Results Conference Call for Investors
Baxter International Inc. (NYSE: BAX) will host a conference call to discuss its second quarter 2018 financial results on Thursday, July 26, 2018, at 7:30 a.m. Central Time. To access the call, dial (844) 886-1929 (domestic) or (225) 239-4663 (international). Please dial into the call at least 10 minutes prior to the start for the operator to connect you. The Conference ID is 2998733.
Baxter Releases 2017 Corporate Responsibility Report and Reinforces its Commitment to Enriching Communities Around the World
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today released its 2017 Corporate Responsibility Report, highlighting its efforts to create lasting social, economic and environmental value in the communities the company serves around the world.
Baxter Unveiled Updates to SHARESOURCE Remote Patient Management Platform for Home Dialysis Patients at ERA-EDTA 2018
Baxter International Inc. (NYSE: BAX), a global innovator in renal care, announced the availability of two program updates for its SHARESOURCE remote patient management platform to support greater accessibility and efficiencies in remotely viewing patient data.
Baxter Supported Nine New Abstract Presentations at the 55th ERA-EDTA Congress that Further Demonstrate Value of HDX Therapy Enabled by THERANOVA
Baxter International Inc. (NYSE: BAX), a global innovator in renal care, announced new data reinforcing that expanded hemodialysis (HDx) enabled by the THERANOVA dialyzer clears large middle molecules at a higher rate when compared to standard hemodialysis (HD), and equivalent or higher removal rates compared to high-volume hemodiafiltration (HDF). Two studies presented also found that albumin levels remained stable during HDx treatment.